Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11736156 | PMC |
| http://dx.doi.org/10.1016/j.jdcr.2024.08.027 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A case of secukinumab-induced psoriasis in a 25-year-old man with improved hidradenitis suppurativa.
JAAD Case Rep
November 2024
Goodman Dermatology, Roswell, Georgia.
Behcet's-like disease induced by secukinumab in a patient with psoriasis: a case report and literature review.
J Dermatolog Treat
December 2024
Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China.
The incidence of cutaneous paradoxical reactions associated with IL-17 inhibitors has gained attention in recent literature. Our report aims to investigate the characteristics of one rare paradoxical reaction, presenting as Behcet's disease. We reported one case of Behcet's-like disease induced by secukinumab in a patient with psoriasis.
View Article and Find Full Text PDFOphiasis Alopecia Areata in a Patient With Spondyloarthritis on Secukinumab: A Case Report and Review of the Literature.
Cureus
February 2024
Dermatology, Mayo Clinic, Rochester, USA.
Secukinumab (Cosentyx), an interleukin-17A-targeting biological agent, is commonly prescribed for psoriasis, psoriatic arthritis, and spondyloarthritis (SpA). Alopecia areata (AA), an IL-17-mediated autoimmune disorder characterized by nonscarring hair loss, particularly in an ophiasis pattern, represents a rare adverse effect associated with secukinumab therapy. We present a case of a 46-year-old female with SpA undergoing secukinumab treatment, who developed an ophiasis pattern of AA, subsequently experiencing regrowth upon medication discontinuation.
View Article and Find Full Text PDFSecukinumab induced colitis resulting in toxic megacolon.
ANZ J Surg
March 2024
Department of Colorectal Surgery, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.
Secukinumab-Induced Alopecia Areata Successfully Treated with Tofacitinib in a Patient with Palmoplantar Pustulosis.
Clin Cosmet Investig Dermatol
October 2023
Department of Rheumatology, Fangshan Hospital Beijing University of Chinese Medicine, Beijing, People's Republic of China.
Secukinumab, a monoclonal antibody targeting interleukin-17 (IL-17), has exhibited encouraging results in the therapeutic management of palmoplantar pustulosis (PPP). The development of alopecia areata (AA) is closely related to IL-17, and IL-17A inhibitors were considered as a potential treatment modality. Therefore, the development of AA during secukinumab treatment for PPP is a rare adverse event that has been rarely reported worldwide.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!